Kbi-092 - __top__

If KBI-092 has successfully passed pre-clinical hurdles, it enters the clinical trial phases, arguably the most rigorous test of any therapeutic candidate.

The most prominent "092" compound in recent medical research is , also known as Miransertib or Zanzalintinib . KBI-092